How to prevent vaginal yeast infection in pregnancy

Vaginal yeast infection (vulvovaginal candidiasis, VVC) is a common cause of vaginal discomfort in women of reproductive age. Pregnancy can increase the likelihood of symptomatic VVC because of physiologic changes in the genital tract. This article reviews the pathophysiology, clinical presentation, diagnosis, treatment considerations during pregnancy, and evidence-based prevention strategies to reduce the risk of recurrent or new yeast infections while pregnant. Information and recommendations are framed for medical education and are based on guidance from recognized clinical sources (ACOG, NIH/MedlinePlus, Mayo Clinic, Cleveland Clinic) and contemporary clinical practice.

Overview: what is vulvovaginal candidiasis?

Vulvovaginal candidiasis is an overgrowth of Candida species (most commonly Candida albicans) in the vulvovaginal region. Candida species are part of the normal vaginal flora in many women, but under certain conditions they can proliferate and produce symptomatic infection. Typical local symptoms include vulvar and vaginal pruritus (itching), burning, irritation, and a characteristic vulvovaginal discharge that is often described as thick and curd-like. VVC is not considered a sexually transmitted infection but sexual activity can influence vaginal microenvironment and symptoms.

Pregnancy predisposes to VVC due to hormonal and immunologic changes: elevated estrogen and glycogen content in vaginal epithelial cells favor Candida adherence and growth, and the local immune response is altered. These changes may increase both incidence and severity of symptomatic episodes during pregnancy.

(See professional resources: ACOG Practice Bulletins; MedlinePlus/NIH; Mayo Clinic patient information.)

Why pregnancy increases the risk

Several physiologic and behavioral factors during pregnancy increase the likelihood of symptomatic candidiasis:

• Elevated estrogen levels: Estrogen increases glycogen deposition in vaginal epithelial cells; glycogen breakdown produces glucose that facilitates Candida growth and adherence.
• Altered immune response: Pregnancy involves immune modulation that can reduce local cellular immune responses against fungi.
• Changes in vaginal microbiota: The balance between Lactobacillus species (protective) and other organisms may be altered, facilitating Candida overgrowth.
• Higher vaginal pH in some cases: While pH in VVC often remains acidic (≤4.5), any disturbances of the normal environment may permit overgrowth.
• Increased frequency of antibiotic use in pregnancy: Systemic or vaginal antibiotics that suppress bacterial flora can allow opportunistic fungal proliferation.
• Underlying medical conditions: Diabetes mellitus or corticosteroid exposure increase Candida risk, and glycemic control often changes during pregnancy.

Clinical sources including ACOG and Mayo Clinic recognize that pregnant people may experience more frequent or severe episodes of VVC compared with non-pregnant individuals.

Typical symptoms and clinical presentation

Recognizing the common features helps distinguish VVC from other causes of vaginal symptoms:

Common signs and symptoms of vulvovaginal candidiasis

• Intense vulvar and vaginal itching (often persistent)
• Vulvar burning or soreness, particularly with friction or urination
• Erythema and swelling of the vulva and labia
• Thick, white, clumpy vaginal discharge described as "cheesy" or curd-like
• Normal or slightly acidic vaginal pH (typically ≤4.5)
• Absence of unpleasant odor in uncomplicated VVC (unlike bacterial vaginosis)
• Symptoms may worsen in the luteal phase in nonpregnant women; in pregnancy symptoms may be more sustained

Symptoms that suggest an alternative diagnosis or additional evaluation:

• Foul-smelling or fishy discharge (suggests bacterial vaginosis)
• Copious watery or frothy discharge (suggests trichomoniasis)
• Pelvic pain, fever, or systemic symptoms (require urgent evaluation)
• Recurrent episodes (≥4 episodes per year) or persistent symptoms after appropriate treatment

Always discuss new or concerning symptoms with a healthcare provider. Self-diagnosis can be inaccurate—particularly in pregnancy—so clinical evaluation and appropriate testing are recommended prior to initiating therapy.

Diagnosis during pregnancy

Accurate diagnosis improves treatment selection and outcomes. Diagnostic steps commonly used in clinical practice include:

• Clinical history and physical exam: Document symptoms, onset, prior treatments, antibiotic exposure, diabetes, immunosuppression, and sexual history.
• Speculum and pelvic exam: Visualize vulvar, vaginal, and cervical findings; assess character of discharge.
• Office testing:
• Vaginal pH testing: VVC typically presents with pH ≤4.5.
• Microscopy with wet mount and 10% KOH (potassium hydroxide) preparation: KOH dissolves cellular debris and enhances visualization of budding yeast or pseudohyphae.
• Gram stain or saline wet mount can identify yeast in some cases; the KOH prep is more sensitive for fungal elements.
• Vaginal culture or nucleic acid amplification testing (NAAT): Reserved for recurrent, refractory, or atypical cases, or if non-albicans Candida species are suspected. Culture can guide antifungal selection because non-albicans species may be less responsive to azole therapy.
• Consider testing for other pathogens: If symptoms or risk factors suggest bacterial vaginosis, trichomoniasis, or STIs, appropriate testing should be performed.

In pregnancy, confirmatory testing before treatment is advisable because some therapies are avoided or selected carefully due to fetal safety concerns.

(References: ACOG practice bulletins; MedlinePlus/NIH; Mayo Clinic clinical guidance.)

Treatment considerations in pregnancy

Treatment choices in pregnancy should balance maternal symptom relief with fetal safety. The mainstay of treatment for VVC in pregnancy is topical azole antifungal therapy.

• Recommended first-line therapy in pregnancy:
• Topical intravaginal azoles (imidazole or triazole formulations) such as clotrimazole or miconazole applied as creams, suppositories, or tablets. Typical regimens range from short courses (1–3 days) to longer courses (7 days) depending on the product and formulation. Extended 7-day topical therapy is commonly used for pregnant patients because it increases efficacy and reduces recurrence.
• Topical azoles are considered effective and safe during pregnancy when used as directed.

• Oral fluconazole:
• Oral fluconazole is an effective single-dose therapy for uncomplicated VVC in nonpregnant patients, but systemic exposure and potential teratogenic risk have prompted caution in pregnancy. High-dose or multiple-dose fluconazole exposure in early pregnancy has been associated in some reports with rare congenital anomalies. Therefore, oral fluconazole is generally avoided during pregnancy unless there is a compelling reason and a specialist's recommendation.
• ACOG and other authorities recommend topical azole therapy rather than systemic azole therapy during pregnancy.

• Management of recurrent or refractory VVC during pregnancy:
• Recurrent VVC (≥4 symptomatic episodes per year) requires evaluation for underlying risk factors such as diabetes, immune suppression, or colonization by non-albicans species. Culture-directed therapy may be required.
• Some suppressive regimens (e.g., weekly topical azole) may be used postpartum or in nonpregnant patients; during pregnancy, individualized management is necessary and specialist consultation is advised.

• Nonpharmacologic measures:
• Avoidance of irritants and practices that disrupt the vaginal microbiome,
• Optimizing glycemic control in diabetes,
• Limiting unnecessary systemic antibiotics.

Refer to ACOG recommendations and institutional guidelines for precise dosing and specific product guidance.

(References: ACOG Practice Bulletins; Mayo Clinic patient information; Cleveland Clinic.)

Prevention strategies for vaginal yeast infections during pregnancy

Prevention focuses on minimizing risk factors, preserving normal vaginal flora, and reducing conditions that favor Candida overgrowth. The following evidence-informed measures can reduce the likelihood of symptomatic VVC in pregnancy.

1. Maintain genital hygiene without disrupting the vaginal ecosystem

• Avoid douching: Douching disrupts the normal vaginal flora and can increase the risk of infections and adverse pregnancy outcomes. It is discouraged by major medical organizations.
• Use gentle, unscented cleansers: Clean the external vulvar area with mild, fragrance-free soap and water. Avoid scented washes, feminine hygiene sprays, or powders that can irritate the vulva or alter microflora.
• Pat dry after bathing: Moist environments promote growth of fungi; gently pat the vulva dry rather than rubbing.

(References: ACOG; Mayo Clinic.)

2. Choose breathable, moisture-wicking clothing and underwear

• Wear cotton or moisture-wicking underwear: Cotton allows better air circulation and reduces moisture retention. Synthetic, tight-fitting underwear and leggings can trap moisture and heat, creating a favorable environment for Candida.
• Avoid prolonged wearing of damp clothing: Change out of wet swimsuits or exercise clothes promptly.
• Choose loose-fitting clothing when possible: Tight pants and nonbreathable fabrics increase warmth and moisture.

(References: Cleveland Clinic; Mayo Clinic.)

3. Manage blood glucose and diabetes carefully

• Maintain glycemic control: Hyperglycemia increases vaginal glucose and predisposes to Candida overgrowth.
• Pregnant patients with pre-existing diabetes or gestational diabetes should follow prenatal care recommendations for monitoring and management, including diet, glucose monitoring, and medication adjustments as advised by obstetric care providers.

(References: NIH/MedlinePlus; ACOG.)

4. Avoid unnecessary antibiotics and coordinate their use with your clinician

• Use antibiotics judiciously: Broad-spectrum antibiotics can suppress protective lactobacilli in the vagina and permit fungal overgrowth. If antibiotics are necessary, discuss potential risks and preventive measures with your provider.
• Consider prophylactic measures where clinically indicated: For those with a history of recurrent VVC who require prolonged antibiotics, a clinician may discuss strategies to reduce yeast overgrowth, such as monitoring and early treatment at the first sign of symptoms.

(References: ACOG; Cleveland Clinic.)

5. Avoid vaginal products that alter pH or introduce irritants

• Refrain from scented tampons, pads, and panty liners: These products can contain fragrances and chemicals that irritate the vulvar skin and mucosa.
• Avoid intravaginal antiseptics, deodorants, or strongly perfumed products: Such agents can be disruptive and are not recommended during pregnancy.

(References: Mayo Clinic; ACOG.)

6. Sexual activity and condom use

• Sexual activity does not directly cause VVC but can mechanically irritate the vulvar tissues and introduce microenvironmental changes. If symptoms are present, abstain from sexual activity until vulvovaginal symptoms resolve.
• Use condoms if there are concerns about partner colonization or if partners have genital symptoms. Candida can transiently colonize male partners; treatment is typically not required unless symptomatic.

(References: ACOG; Cleveland Clinic.)

7. Consider evidence-based adjuncts with caution

• Probiotics: Some studies suggest that oral or intravaginal Lactobacillus-containing probiotics may help restore normal vaginal flora and reduce recurrence rates in select populations. However, evidence is mixed and not definitive. Probiotic products vary widely; patients should discuss use with their provider to choose an appropriate product and formulation.
• Dietary changes: Limiting excessive dietary sugars and refined carbohydrates may help, particularly for individuals with or at risk for hyperglycemia, although direct evidence is limited.
• Boric acid: Vaginal boric acid can be effective for refractory, non-albicans VVC but is considered contraindicated during pregnancy because safety data are insufficient. Do not use boric acid during pregnancy.

(References: NIH/MedlinePlus; Mayo Clinic; Cleveland Clinic.)

8. Prompt evaluation of symptoms and testing when indicated

• Early clinical evaluation: Seek medical assessment early if vulvar itching, burning, or unusual discharge develops. Prompt diagnosis allows targeted therapy that reduces symptom duration and helps prevent complications.
• Laboratory confirmation for atypical or recurrent presentations: Cultures or NAATs can identify non-albicans Candida species or other pathogens that require alternative therapy.

(References: ACOG; MedlinePlus/NIH.)

Special situations and considerations

Recurrent vulvovaginal candidiasis in pregnancy

Recurrent symptomatic VVC (≥4 episodes per year) requires a comprehensive approach:

• Evaluate for underlying causes: Diabetes, immunodeficiency, medications, or colonization with non-albicans species.
• Perform targeted testing: Culture and species identification may be necessary to guide treatment because some non-albicans species (e.g., Candida glabrata) are less azole-sensitive.
• Individualize management: Suppressive therapy options often used outside pregnancy need careful consideration in pregnancy and may be deferred until postpartum unless symptoms are severe. Collaboration with obstetrics and infectious disease specialists is recommended.

(References: ACOG; Cleveland Clinic.)

Neonatal considerations

• Peripartum colonization: Mothers with symptomatic VVC at the time of delivery can transmit Candida to the neonate, potentially causing oral thrush or diaper dermatitis. While maternal VVC is uncomfortable, it is generally not associated with major adverse pregnancy outcomes. Neonatal management is typically local antifungal therapy as indicated.
• Counseling and treatment planning: If VVC is present near delivery, discuss neonatal risks and options with your obstetric provider. Treatment during pregnancy to relieve maternal symptoms is appropriate and recommended in most cases.

(References: ACOG; Mayo Clinic.)

When to seek urgent care

Seek urgent evaluation if you experience:

• Fever, chills, or systemic symptoms
• Severe pelvic pain or heavy vaginal bleeding
• Foul-smelling or profuse discharge
• Signs of ascending or complicated infection

These symptoms are not characteristic of uncomplicated VVC and may indicate alternative or concomitant pathology.

Practical, step-by-step prevention plan for pregnant patients

1. Schedule regular prenatal visits and report any vulvovaginal symptoms promptly.
2. Use gentle external cleansing with mild, fragrance-free soap and water; avoid douching.
3. Wear breathable cotton underwear and loose-fitting clothing; change out of damp clothes promptly.
4. Maintain good glycemic control if you have preexisting or gestational diabetes.
5. Avoid unnecessary systemic antibiotics; when antibiotics are medically required, monitor for symptoms and contact your provider early if itching or abnormal discharge develops.
6. Use intravaginal topical azole therapy only under provider guidance if symptoms develop; avoid oral azole treatment in pregnancy unless advised by a specialist.
7. Avoid scented feminine products, lubricants with perfumes, and intravaginal spermicides that can irritate mucosa.
8. Discuss probiotic use with your healthcare provider if you are interested in adjunctive preventive measures; do not self-prescribe nonstandard vaginal treatments.
9. For recurrent or refractory symptoms, request vaginal culture and specialist consultation to identify species and tailor therapy.

Myths and misconceptions

• “Douching prevents infections.” False. Douching increases the risk of infection and should be avoided during pregnancy.
• “All vaginal discharge in pregnancy is an infection.” False. Increased physiologic vaginal discharge is common in pregnancy. However, new onset of itchy, burning symptoms or abnormal discharge should be evaluated.
• “You must treat sexual partners.” Partner treatment for candidiasis is usually not necessary unless the partner has symptoms. Discuss partner management with your provider.

Summary

Vulvovaginal candidiasis is common during pregnancy because hormonal and immunologic changes favor Candida overgrowth. The most reliable prevention measures focus on preserving the normal vaginal environment and minimizing risk factors: avoid douching and scented products, wear breathable clothing, maintain glycemic control, use antibiotics only when indicated, and seek early evaluation for symptoms. In pregnancy, topical intravaginal azole therapy (e.g., clotrimazole, miconazole) is the preferred treatment; systemic fluconazole is generally avoided. For recurrent or atypical cases, culture-directed therapy and specialist consultation are recommended.

If you are pregnant and experiencing vulvovaginal symptoms, consult your obstetric provider or gynecologist for evaluation and personalized management.

References

• American College of Obstetricians and Gynecologists (ACOG). Practice Bulletins and Committee Opinions on vaginal infections and prenatal care. Available at: https://www.acog.org
• U.S. National Library of Medicine / MedlinePlus (NIH). Vaginitis; Yeast infection. Available at: https://medlineplus.gov/vaginitis.html and https://medlineplus.gov/ency/article/001339.htm
• Mayo Clinic. Yeast infection (vaginal candidiasis) — Symptoms and causes; Pregnancy and yeast infections. Available at: https://www.mayoclinic.org/diseases-conditions/yeast-infection
• Cleveland Clinic. Vaginal yeast infection — Overview, symptoms, treatment, prevention. Available at: https://my.clevelandclinic.org/health/diseases/21118-yeast-infection
• Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections Treatment Guidelines — Vulvovaginal candidiasis. (Useful clinical guidance regarding diagnosis and treatment options outside pregnancy.) Available at: https://www.cdc.gov/std/treatment-guidelines/default.htm

(If you have specific symptoms or recurrent infections, please consult your obstetrical provider for individualized medical advice.)